Therapy of paraneoplastic disorders of the CNS

References

• Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-40
   PubMed Web of Science ®Google Scholar
• Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. JNNP 2012;83(6):638-45
   PubMed Web of Science ®Google Scholar
• Irani S, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann neurol 2014;76:168-84
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad SS, Brilot F, Dale RC. Autoimmune encephalitis: recent updates and emerging challenges. J Clini Neurosci 2014;21(5):722-30
   PubMed Web of Science ®Google Scholar
• Vedeler CA, Antoine JC, Gionetto B, et al. for the Paraneoplastic neurological syndrome Euronetwork Paraneoplastic neurological syndromes Chapter 31. in Gilhaus NE, Barnes MP, Brainin M, editors. European Handbook or Neurological Management. Volume 1, 2nd edition. Handbook of Blackwell Publishing Ltd, Vienna, Austria; 2011. pp. 447-57
   Google Scholar
• Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010;257:509-17
   PubMed Web of Science ®Google Scholar
• McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011;122:381-400
   Google Scholar
• Dalmau J, Rosenfeld J. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327-40
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014;175:336-48
   PubMed Web of Science ®Google Scholar
• McKeon A. Paraneoplastic and other autoimmune disorders of the central nervous system. The Neurohospitalist 2012;3:53-64
   Google Scholar
• Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127:701-12
   PubMed Web of Science ®Google Scholar
• Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy for VGKC antibody-positive limbic encephalitis. JNNP 2010;81(10):1167-9
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken LM, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157-65
   PubMed Web of Science ®Google Scholar
• Shams’ili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-18
   PubMed Web of Science ®Google Scholar
• Honnorat J, Cartalat-Cartel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neuorolgical symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. JNNP 2009;80:412-16
   PubMed Web of Science ®Google Scholar
• Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centres. Arch Neurol 2010;67(3):330-5
   PubMedGoogle Scholar
• Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti Hu associated paraneoplastic encephalomyeltis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992;71:59-72
   PubMed Web of Science ®Google Scholar
• Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(Pt 6):1138-48
   PubMed Web of Science ®Google Scholar
• Douglas CA, Ellershaw J. Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small-cell lung cancer. Palliat Med 2003;17:638-9
   Google Scholar
• Bernal F, Shams’ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology 2003;60:230-4
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006;28:585-93
   PubMed Web of Science ®Google Scholar
• Pranzatelli MR, Tate ED, Dukart WS, et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005;147:372-8
   PubMed Web of Science ®Google Scholar
• Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus - myoclonus. Brain 2001;124:437-43
   PubMed Web of Science ®Google Scholar
• Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features – correlation of clinical improvement with tumor response. Cancer Invest 2004;22:257-61
   PubMed Web of Science ®Google Scholar
• Straube A, Leigh RJ, Bronstein A, et al. EFNS task force -therapy of nystagmus and oscillopsia. Eur J Neurol 2004;11:83-9
   PubMed Web of Science ®Google Scholar
• Vincent A, Bien CG, Irani S, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759-72
   PubMed Web of Science ®Google Scholar
• Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133(9):2734-48
   PubMed Web of Science ®Google Scholar
• Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008;131:2553-63
   PubMed Web of Science ®Google Scholar
• Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014;137:2178-92
   PubMed Web of Science ®Google Scholar
• Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-75
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655-67
   PubMed Web of Science ®Google Scholar
• Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. J Neurology 2014;82(7):556-63
   Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63-74
   PubMed Web of Science ®Google Scholar
• Iluzuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal Neurology. 2008;70:504-11
   Google Scholar
• Armangue T, Leypoldt F, Málaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014;75:317-23
   PubMed Web of Science ®Google Scholar
• Badzek S, Miletic V, Prejac J, et al. Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson’s disease worsened after capecitabine therapy. World J Surg Oncol 2013;11:224
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Fujii M, Li M, et al. The clinical spectrum of anti-GAD antibody -positive patients with stiff-person syndrome. Neurology 2000;55:1531-5
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-6
   PubMed Web of Science ®Google Scholar
• Baker MR, Das M, Isaacs J, et al. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatr 2005;76:999-1001
   PubMed Web of Science ®Google Scholar